Equity Profile

KYMR

Kymera Therapeutics, Inc.

Health CareBiotechnology$8.8B

Aug10Mon

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Kymera Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies to treat diseases by targeting specific proteins....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs.

N/A

Revenue

Revenue growth is essential for assessing the company's market traction and overall health.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

KYMR Q2-2026 Earnings Preview

Context

Company Snapshot

Kymera Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies to treat diseases by targeting specific proteins. As part of the health care sector, its work is crucial in advancing treatments that could significantly improve patient outcomes.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-4.04%

Avg Stock Reaction

-3.15%

Last Quarter Recap

In Q1-2026, Kymera reported an EPS of -$0.71, which was better than analysts' expectations of -$0.89. However, revenue figures were not disclosed, leaving some uncertainty about overall performance.

Management Promises & Guidance

Expectations

Wall Street Expectations

With no analyst estimates available, expectations for this quarter are uncertain. The stock has shown mixed reactions to past earnings, indicating potential volatility.

Bull Case

If Kymera can demonstrate significant progress in its drug development pipeline, it could lead to positive investor sentiment and stock appreciation.

Bear Case

Conversely, if the company fails to meet expectations or provide clarity on its financials, it may face negative reactions from investors.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of Kymera's drug pipeline and any upcoming clinical trial results?

Investors will closely watch for updates that could indicate the potential for future revenue and market success.

Will there be any guidance on expected revenue growth or changes in operating expenses?

Clear guidance can help set realistic expectations for investors and influence stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential impact of Kymera's drug pipeline advancements, which could lead to significant revenue growth sooner than anticipated.

Supporting Evidence

The company's recent EPS surprise indicates better-than-expected cost management.

Options pricing suggests a larger move than historical averages, indicating heightened investor interest.

The lack of analyst estimates may create an opportunity for unexpected positive news.

Key Risk

If Kymera announces a successful trial result, it could shift market expectations dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Kymera can turn its promising drug pipeline into tangible financial results.

Bull Confirmed If

Demonstrating a clear path to profitability with a reduction in EPS losses to below -$0.60.

Bear Confirmed If

If EPS losses exceed -$0.80, it could signal deeper issues within the company.

Pre-Earnings Positioning

Options Market

Implied Move

±23.64%

Historical Avg

±4.4%

Pricing rich

The options market is pricing in a significant move, suggesting that investors are anticipating volatility around the earnings report.

Options are pricing ±23.6% while KYMR has averaged ±4.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

34.0%

Calls (0)P/C Ratio: 1.00Puts (14K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Kymera beats expectations, history suggests a potential average move of +2.16% on the first day, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may see limited movement as investors await further clarity from management.

Miss

Should the company miss expectations, history indicates an average decline of -4.14%, reflecting negative investor sentiment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status of clinical trials and drug development timelines.
2Any guidance on expected revenue growth for the upcoming quarters.
3Details on cost management strategies and operational efficiencies.
4Insights into competitive positioning within the biotechnology sector.
5Management's outlook on market conditions and potential challenges ahead.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug7

PAABMO

Plains All American Pipeline, L.P.

PreviewView

Aug7

ESNTBMO

Company Snapshot

Kymera Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies to treat diseases by targeting specific proteins....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs.

N/A

Revenue

Revenue growth is essential for assessing the company's market traction and overall health.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

KYMR Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-4.04%

Avg Stock Reaction

-3.15%

Last Quarter Recap

In Q1-2026, Kymera reported an EPS of -$0.71, which was better than analysts' expectations of -$0.89. However, revenue figures were not disclosed, leaving some uncertainty about overall performance.

Management Promises & Guidance

Expectations

Wall Street Expectations

With no analyst estimates available, expectations for this quarter are uncertain. The stock has shown mixed reactions to past earnings, indicating potential volatility.

Bull Case

If Kymera can demonstrate significant progress in its drug development pipeline, it could lead to positive investor sentiment and stock appreciation.

Bear Case

Conversely, if the company fails to meet expectations or provide clarity on its financials, it may face negative reactions from investors.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of Kymera's drug pipeline and any upcoming clinical trial results?

Investors will closely watch for updates that could indicate the potential for future revenue and market success.

Will there be any guidance on expected revenue growth or changes in operating expenses?

Clear guidance can help set realistic expectations for investors and influence stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential impact of Kymera's drug pipeline advancements, which could lead to significant revenue growth sooner than anticipated.

Supporting Evidence

The company's recent EPS surprise indicates better-than-expected cost management.

Options pricing suggests a larger move than historical averages, indicating heightened investor interest.

The lack of analyst estimates may create an opportunity for unexpected positive news.

Key Risk

If Kymera announces a successful trial result, it could shift market expectations dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Kymera can turn its promising drug pipeline into tangible financial results.

Bull Confirmed If

Demonstrating a clear path to profitability with a reduction in EPS losses to below -$0.60.

Bear Confirmed If

If EPS losses exceed -$0.80, it could signal deeper issues within the company.

Pre-Earnings Positioning

Options Market

Implied Move

±23.64%

Historical Avg

±4.4%

Pricing rich

The options market is pricing in a significant move, suggesting that investors are anticipating volatility around the earnings report.

Options are pricing ±23.6% while KYMR has averaged ±4.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

34.0%

Calls (0)P/C Ratio: 1.00Puts (14K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Kymera beats expectations, history suggests a potential average move of +2.16% on the first day, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may see limited movement as investors await further clarity from management.

Miss

Should the company miss expectations, history indicates an average decline of -4.14%, reflecting negative investor sentiment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status of clinical trials and drug development timelines.
2Any guidance on expected revenue growth for the upcoming quarters.
3Details on cost management strategies and operational efficiencies.
4Insights into competitive positioning within the biotechnology sector.
5Management's outlook on market conditions and potential challenges ahead.